Aarti Drugs Q4FY22 Quarter Results
Aarti Drugs net revenues grew 39% YoY in Q4FY22.
- 09 May 2022
- Aarti Drugs consolidated revenues for the quarter ended December (Q4FY22) were up 9% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 39%.
- Its expenses for the quarter were up 11% QoQ and 43% YoY.
- While the company reported 5% QoQ net profit decline, the same was up by 7% on a YoY basis.
- The earnings per share (EPS) of Aarti Drugs stood at 6 during Q4FY22.
Aarti Drugs Financial Statements for Q4FY22:
Total Income | 503 | 641 | 697 | 9% | 39% |
Total Expenses | 437 | 563 | 627 | 11% | 43% |
Profit before tax | 65 | 79 | 71 | -10% | 8% |
Tax | 14 | 20 | 15 | -26% | 12% |
Profit after tax | 52 | 58 | 55 | -5% | 7% |
Earnings per share | 5.5 | 6.3 | 6.0 |
Data Source: BSE, Company announcements
Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Neo.
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account